



CytoTools AG announces the first order for the manufacture of DermaPro® for the Indian market.

- Order received for over 130,000 units of DermaPro® for the Indian market
- Together with licensee Centaur Pharmaceuticals, the CytoTools AG board sets the framework conditions for the product launch at a large marketing meeting in Mumbai.
- Road map for the approval and marketing of DermaPro® in India

Darmstadt, 5th December 2013 – Centaur Pharmaceuticals, a partner of the technology holding CytoTools AG, which is active in the pharmaceutical and medical products field, has set the course for the launch of DermaPro® in the Indian market at a large marketing meeting in Mumbai, in November. As well as the final work on submitting the new drug approval, in Mumbai, the packaging, price and marketing strategy were defined. In this connection, the first order to initiate production was placed for 130,000 units of DermaPro® to establish a strategic stock for the Indian market. Furthermore, applications were made for all the necessary approvals for importing to India. Thus all the prerequisites have been met for a successful market launch next year.

The first large order also means the German contract manufacturer of DermaPro® is making all the necessary preparations for production on an industrial scale. Here, in particular, as well as the scale-up of the manufacturing process, further production lines are being set up in order to be able to satisfy the expected demand after market approval. For the time being, the current capacities are to be increased tenfold with the completion of the final extension phase. These steps also mean a substantial extension of production capacities for the manufacturer of DermaPro®. Thus the confidential and very close cooperation of the past years has developed into a successful partnership.

Dr. Dirk Kaiser, joint managing director of CytoTools AG, summarized the results: „We have come a long way in the manufacturing of DermaPro®, from a small pilot production in university laboratories to an industrial production with our partner which meets all the requirements of regulatory authorities worldwide. We are proud now to take this last step together to implement a large scale production for the pharmaceuticals market“.

PRESS RELEASE



CytoTools

Dr. Mark-Andre Freyberg, joint managing director of CytoTools AG, also explained the commercial importance for the company: „With DermaPro®, for the first time physicians have a worldwide patented and very effective drug at their disposal for treating diabetic foot and, after corresponding clinical trials, for treating other large indications in the wound healing field. We therefore presume that DermaPro® has enormous market potential. The first production order will be followed at the beginning of next year by further orders after a price study in the Indian market has been completed. We are now fully concentrating on building up the corresponding capacities to be ready for the market launch in India.“

With this and the further orders for DermaPro® in the coming year, the image of CytoTools AG will evolve from a research and development enterprise to a producing biotechnology/ pharmaceuticals company. The expected revenues from the sale of the new drug and license fees can in the very near future lead to significant revenue and profit developments both for the subsidiary DermaTools Biotech GmbH and the holding CytoTools AG.

This press release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

CytoTools AG, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: around 58% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

PRESS RELEASE



CytoTools

Contact:

CytoTools AG

Dr. Mark Andre Freyberg

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: freyberg@cytotools.de

Press contact:

cometis AG

Ulrich Wiehle

Unter den Eichen 7

D-65195 Wiesbaden

Tel.: +49-611-205855-11

Fax: +49-611-205855-66

E-Mail: wiehle@cometis.de